Inaktiver Wert

Andere Sprachen Oragenics Inc Nyse

Aktien

Oragenics: Q1 Earnings Snapshot	15.05.
Oragenics Partners with Avance Clinical for Phase II Concussion Trial in Australia	07.05.
Oragenics, Inc. Announces Partnership with Avance Clinical to Conduct Phase II Clinical Trial in Australia	07.05.
Oragenics, Inc. Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards	19.04.
North American Morning Briefing : Big Banks Kick -2-	12.04.
Oragenics, Inc. Files 10K and Provides Company Update	01.04.
Oragenics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29.03.
Oragenics Appoints James Kelly MD, Chief Medical Officer, to Lead Phase II Clinical Trials for Treating Concussion	18.03.
Oragenics Appoints James Kelly MD as Chief Medical Officer, to Lead Phase II Clinical Trials for Treating Concussion	18.03.
Oragenics, Inc. Prepares Drug for Phase II Clinical Trials to Treat Concussion	05.03.
Oragenics, Inc. Prepares Drug for Phase II Clinical Trials to Treat Concussion	05.03.
Oragenics Announces Closing of Public Offering	04.03.
Oragenics Announces Closing of Public Offering	01.03.
Top Midday Decliners	28.02.
Oragenics Announces Pricing of Public Offering	28.02.
Oragenics Announces Proposed Public Offering	27.02.
Oragenics CEO Kimberly Murphy Steps Down, Board Chair to Serve as Interim Executive Chair	13.02.
Oragenics, Inc. Announces Leadership Transition	12.02.
Oragenics, Inc. Announces Leadership Transition	12.02.
Oragenics, Inc. Announces CEO Changes	12.02.

Keine Ergebnisse zu dieser Suche